Pittsburgh to Build New Cancer Center

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

PITTSBURGH-To accommodate the growth of the University of Pittsburgh Cancer Institute’s (UPCI’s) treatment and research activities, the UPMC Health System will build a 295,000 square-foot integrated facility on the UPMC Shadyside campus. This $104 million building will serve as the hub for UPCI’s clinical programs and scientific investigations.

PITTSBURGH—To accommodate the growth of the University of Pittsburgh Cancer Institute’s (UPCI’s) treatment and research activities, the UPMC Health System will build a 295,000 square-foot integrated facility on the UPMC Shadyside campus. This $104 million building will serve as the hub for UPCI’s clinical programs and scientific investigations.

UPCI includes more than 600 scientists and health care professionals in more than 30 disciplines. It is the only NCI-designated comprehensive cancer center in western Pennsylvania.

“This new building symbolizes the commitment of the UPMC Health System to combat this disease, which touches every family and which is the second-leading cause of death in the United States,” said Jeffrey Romoff, president of the UPMC.

The new building will more than double current research space and allow for the recruitment of 250 new scientists and clinicians. Groundbreaking on the building will begin in the spring of this year.

Recent Videos
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content